Skip to main content

Articles By Kathryn H. Dao, M.D.

lupus.jpg

How Do You Measure Success When It Comes to SLE?

By Kathryn H. Dao, M.D.
10 June 2021

EULAR 2021 opened with a grand debate to answer this essential question:  should clinicians treat to remission or to Lupus Low Disease Activity State (LLDAS)?  

Read Article
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

Combination vs. Sequential Therapy for the Treatment of Lupus Nephritis

By Kathryn H. Dao, M.D.
08 June 2021

Combination disease modifying antirheumatic drug (DMARD) therapy may not be only for rheumatoid arthritis; combining disease modifying agents may be the path to better renal response. 

Read Article
Meeting audience conference

Future Therapeutics for Rheumatoid Arthritis and Lessons Learned - RNL2021 Highlights

By Kathryn H. Dao, M.D.
24 March 2021

In case you missed it, RheumNow Live 2021 delivers what it promises: a good consistent program pack with high energy interactive learning. In the Day 1 learning pods, the audience was given a tour of the new drugs in development for RA.

Read Article
gavel judgement decide gold

Rebuttals

By Kathryn H. Dao, M.D.
15 March 2021

Since the COVID vaccine rollout, more people have been eligible to receive the vaccine. However, not everyone chooses to get one. I have heard many reasons (aka excuses) from my patients who are vaccine hesitant. 

Read Article
covid vaccine

Best of 2020: My Experience as a COVID19 Vaccine Trial Participant

By Kathryn H. Dao, M.D.
28 December 2020

I have been an investigator for many clinical rheumatology studies over the past two decades but have never been a study subject until now. On October 31, 2020, I enrolled in the phase 3 trial of the Pfizer/BioNTech mRNA vaccine against SARS-CoV2 (protocol C4591001). Here's my experience.

Read Article
registry.jpg

Best of 2020: The COVID-19 Global Rheumatology Registry

By Kathryn H. Dao, M.D.
24 December 2020

What started out as online tweets and sharing newsfeed and case reports, has progressed to the formation of the COVID-19 Global Rheumatology Alliance, whose mission is to create an international rheumatology registry of patients affected by the disease in order to better understand the disease and guide clinicians in assessing and treating patients. 

Read Article
doctor-4861811_1280.jpg

Best of 2020: A Rheumatologist’s Tips: Telemedicine in 6 Easy Steps

By Kathryn H. Dao, M.D.
23 December 2020

Ready for telemedicine/telerheumatology? Once you and your patient agree on a virtual visit, the following suggestions may help facilitate the interaction. If you have the ability and the capacity, record the visit.

Read Article
covid vaccine

My Experience as a COVID19 Vaccine Trial Participant

By Kathryn H. Dao, M.D.
01 December 2020

I have been an investigator for many clinical rheumatology studies over the past two decades but have never been a study subject until now. On October 31, 2020, I enrolled in the phase 3 trial of the Pfizer/BioNTech mRNA vaccine against SARS-CoV2 (protocol C4591001). Here's my experience.

Read Article
influenza-156098_640.png

Flu and Tofacitinib

By Kathryn H. Dao, M.D.
19 November 2020

Dr. Kathryn Dao reviews abstract L04 - Influenza Adverse Events in Patients with Rheumatoid Arthritis in the Tofacitinib Clinical Program - at the 2020 ACR annual meeting.

Read Article
ACR20 Capitol

A Convergence of Ideas: COVID19 and ACR

By Kathryn H. Dao, M.D.
05 November 2020

Since the beginning of the pandemic, rheumatologists scrambled to figure out how the SARS-CoV-2 virus will affect their patients with immune mediated inflammatory diseases (IMID). Meeting the needs of patients, managing a practice, and trying to balance a home life have many doctors stressed.

Read Article
×